Physician profile
Anne M Eylar
NPI 1174784326
$3,284.55
in general payments reported to CMS, 2019-2025
22 companies · $829 in 2025
The $829 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $174 · 2021: $378 · 2022: $440 · 2023: $563 · 2024: $738 · 2025: $829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,129.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $387.12 | 2021-2025 | Ce-Marked Kxla System |
| Alcon Vision LLC | $351.26 | 2022-2025 | Tryptyr, Rocklatan, Clareon |
| Sight Sciences, INC. | $347.65 | 2020-2025 | Omni Surgical System, Tearcare System |
| Abbvie INC. | $275.95 | 2024-2025 | |
| Rxsight INC | $255.98 | 2022-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Biotissue Holdings INC. | $207.35 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $205.05 | 2022-2024 | Miebo, Xiidra, Vyzulta |
| Harrow Eye, LLC | $181.51 | 2023-2024 | Vevye, Iheezo |
| Astellas Pharma US INC | $169.15 | 2023-2024 | Izervay |
| Dompe US, INC. | $147.09 | 2024 | Oxervate |
| Sun Pharmaceutical Industries INC. | $146.42 | 2019-2025 | Cequa |
| Genentech USA, INC. | $126.35 | 2021-2024 | Vabysmo |
| Johnson & Johnson Vision Care, INC. | $117.29 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $89.42 | 2024-2025 | Acthar |
| Tarsus Pharmaceuticals, INC. | $84.27 | 2024-2025 | Xdemvy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $47.29 | 2024-2025 | Purified Cortrophin Gel, Iluvien |
| Oyster Point Pharma, INC. | $41.32 | 2022-2024 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $33.72 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $25.81 | 2025 | Syfovre |
| The Cameron-Ehlen Group, INC. | $16.24 | 2021 | |
| Allergan, INC. | $15.33 | 2019 | |
| Aerie Pharmaceuticals, INC. | $12.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Eylar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.